TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncolytics Biotech ( (ONCY) ) has shared an update.
On November 20, 2025, Oncolytics Biotech announced the cancellation and rescheduling of its special meeting of shareholders initially planned for December 15, 2025. The decision was due to delays at the Securities and Exchange Commission caused by a recent U.S. federal government shutdown. The meeting, once rescheduled, will address a series of transactions, including the company’s proposed jurisdiction change from Alberta, Canada, to Nevada, USA. This move could significantly impact Oncolytics’ operational jurisdiction and strategic positioning.
The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors for metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA. Oncolytics is also pursuing strategic partnerships to enhance development and commercial impact.
Average Trading Volume: 1,044,354
Technical Sentiment Signal: Hold
Current Market Cap: $110.4M
For an in-depth examination of ONCY stock, go to TipRanks’ Overview page.